Minerva Neurosciences Inc (NERV) - Net Assets
Based on the latest financial reports, Minerva Neurosciences Inc (NERV) has net assets worth $-254.01 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($94.03 Million) and total liabilities ($348.04 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Minerva Neurosciences Inc (NERV) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-254.01 Million |
| % of Total Assets | -270.15% |
| Annual Growth Rate | N/A |
| 5-Year Change | -1864.72% |
| 10-Year Change | -232.8% |
| Growth Volatility | 31806.59 |
Minerva Neurosciences Inc - Net Assets Trend (2012–2025)
This chart illustrates how Minerva Neurosciences Inc's net assets have evolved over time, based on quarterly financial data. See Minerva Neurosciences Inc (NERV) liquidity interval to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Minerva Neurosciences Inc (2012–2025)
The table below shows the annual net assets of Minerva Neurosciences Inc from 2012 to 2025. For live valuation and market cap data, see market value of Minerva Neurosciences Inc.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-140.75 Million | -447.80% |
| 2024-12-31 | $-25.69 Million | +9.71% |
| 2023-12-31 | $-28.46 Million | -42.12% |
| 2022-12-31 | $-20.02 Million | -351.07% |
| 2021-12-31 | $7.98 Million | -84.86% |
| 2020-12-31 | $52.66 Million | +89.57% |
| 2019-12-31 | $27.78 Million | -69.22% |
| 2018-12-31 | $90.26 Million | -31.41% |
| 2017-12-31 | $131.60 Million | +24.17% |
| 2016-12-31 | $105.98 Million | +91.58% |
| 2015-12-31 | $55.32 Million | +7.42% |
| 2014-12-31 | $51.50 Million | +155.21% |
| 2013-12-31 | $20.18 Million | +106002.33% |
| 2012-12-31 | $19.02K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Minerva Neurosciences Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 67423195400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $4.33K | % |
| Other Components | $548.05 Million | % |
| Total Equity | $-140.75 Million | 100.00% |
Minerva Neurosciences Inc Competitors by Market Cap
The table below lists competitors of Minerva Neurosciences Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Tureks Turizm Tasimacilik AS
IS:TUREX
|
$195.21 Million |
|
Bleichroeder Acquisition Corp. I Class A Ordinary Shares
NASDAQ:BACQ
|
$195.26 Million |
|
Korea Asset In Trust Co Ltd
KO:123890
|
$195.29 Million |
|
First Hotel Co Ltd
TW:2706
|
$195.33 Million |
|
Alx Oncology Holdings
NASDAQ:ALXO
|
$195.12 Million |
|
Yuan Jen Enterprises Co Ltd
TW:1725
|
$195.06 Million |
|
HUYA Inc
F:HY5A
|
$194.95 Million |
|
China Ecotek Corp
TW:1535
|
$194.93 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Minerva Neurosciences Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -25,693,100 to -140,748,082, a change of -115,054,982.
- Net loss of 293,423,177 reduced equity.
- New share issuances of 80,000,000 increased equity.
- Other factors increased equity by 98,368,195.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-293.42 Million | -208.47% |
| Share Issuances | $80.00 Million | +56.84% |
| Other Changes | $98.37 Million | +69.89% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Minerva Neurosciences Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | $0.01 | $4.19 | x |
| 2013-12-31 | $8.83 | $4.19 | x |
| 2014-12-31 | $22.17 | $4.19 | x |
| 2015-12-31 | $18.90 | $4.19 | x |
| 2016-12-31 | $26.91 | $4.19 | x |
| 2017-12-31 | $27.75 | $4.19 | x |
| 2018-12-31 | $18.61 | $4.19 | x |
| 2019-12-31 | $5.70 | $4.19 | x |
| 2020-12-31 | $10.30 | $4.19 | x |
| 2021-12-31 | $1.49 | $4.19 | x |
| 2022-12-31 | $-3.75 | $4.19 | x |
| 2023-12-31 | $-4.37 | $4.19 | x |
| 2024-12-31 | $-3.39 | $4.19 | x |
| 2025-12-31 | $-16.63 | $4.19 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Minerva Neurosciences Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-677.45%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -8318.00% | 0.00% | 0.00x | 11.01x | $-1.58 Million |
| 2013 | -16.16% | 0.00% | 0.00x | 1.45x | $-5.28 Million |
| 2014 | -110.49% | 0.00% | 0.00x | 1.33x | $-62.05 Million |
| 2015 | -48.96% | 0.00% | 0.00x | 1.49x | $-32.61 Million |
| 2016 | -29.29% | 0.00% | 0.00x | 1.25x | $-41.64 Million |
| 2017 | -23.95% | 0.00% | 0.00x | 1.40x | $-44.68 Million |
| 2018 | -55.58% | 0.00% | 0.00x | 1.54x | $-59.20 Million |
| 2019 | -259.84% | -175.31% | 0.53x | 2.79x | $-74.96 Million |
| 2020 | 3.69% | 4.71% | 0.71x | 1.09x | $-3.33 Million |
| 2021 | -625.73% | 0.00% | 0.00x | 9.67x | $-50.70 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-30.11 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-27.16 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $4.01 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-279.35 Million |
Industry Comparison
This section compares Minerva Neurosciences Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $155,285,360
- Average return on equity (ROE) among peers: -101.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Minerva Neurosciences Inc (NERV) | $-254.01 Million | -8318.00% | N/A | $195.21 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-34.80 Million | 0.00% | 0.00x | $83.17 Million |
| Abcellera Biologics Inc (ABCL) | $830.51 Million | 14.32% | 0.21x | $1.61 Billion |
| Abeona Therapeutics Inc (ABEO) | $-26.99 Million | 0.00% | 0.00x | $321.39 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $155.29 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $1.01 Billion |
| Arbutus Biopharma Corp (ABUS) | $182.50 Million | -46.25% | 0.30x | $831.63 Million |
| ABVC Biopharma Inc (ABVC) | $4.59 Million | -357.76% | 1.38x | $35.10 Million |
| Abivax SA American Depositary Shares (ABVX) | $33.94 Million | -14.97% | 0.12x | $7.98 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.66 Billion |
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more